UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07

Thoracic cancer, 2020-12, Vol.11 (12), p.3482-3489

2020

Volltextzugriff (PDF)

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Journal of clinical oncology, 2020-02, Vol.38 (5), p.488-495

2020

Volltextzugriff (PDF)

Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection

International journal of cancer, 2012-02, Vol.130 (4), p.948-958

2012

Volltextzugriff (PDF)

Differential efficacy of tyrosine kinase inhibitors (TKIs) according to the types of EGFR mutations and agents in non-small cell lung cancer (NSCLC): A real-world study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21040-e21040

2023

Volltextzugriff (PDF)

Analysis of thromboembolic events in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: A single-center real-world study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e20580-e20580

2024

Volltextzugriff (PDF)

Comparison of preoperative and prechemotherapy lymphocyte counts to predict outcome of non-small cell lung cancer patients treated with adjuvant chemotherapy

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20002-e20002

2019

Volltextzugriff (PDF)

Does the extent of brain metastasis affect outcome of non-small cell lung cancer patients treated with chemotherapy?

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20616-e20616

2019

Volltextzugriff (PDF)

Should combination chemotherapy be used in all advanced gastric cancer patients?

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e16081-e16081

2018

Volltextzugriff (PDF)

Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in gastric cancer patients who underwent palliative chemotherapy

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e16008-e16008

2018

Volltextzugriff (PDF)

Is third-line chemotherapy routine practice in recurrent or metastatic gastric cancer?

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e15558-e15558

2017

Volltextzugriff (PDF)

The role of third-line chemotherapy in recurrent or metastatic gastric cancer: A cohort study with propensity score matching analysis

Medicine (Baltimore), 2018-09, Vol.97 (39), p.e12588-e12588

2018

Volltextzugriff (PDF)

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15109-e15109

2015

Volltextzugriff (PDF)

PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS587-TPS587

2017

Volltextzugriff (PDF)

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e15056-e15056

2014

Volltextzugriff (PDF)

High expression of Bcl-2 to predict poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving CHOP-based chemotherapy

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e19511-e19511

2015

Volltextzugriff (PDF)

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

Acta oncologica, 2015-01, Vol.54 (8), p.1231-1234

2015

Volltextzugriff (PDF)

High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program

Cancer, 2021-08, Vol.127 (16), p.3019-3028

2021

Volltextzugriff (PDF)

MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

European journal of immunology, 2020-11, Vol.50 (11), p.1810-1819

2020

Volltextzugriff (PDF)

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial

Journal of clinical oncology, 2019-08, Vol.37 (24), p.2162-2170

2019

Volltextzugriff (PDF)

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non‐small cell lung cancer

European journal of immunology, 2021-04, Vol.51 (4), p.956-964

2021

Volltextzugriff (PDF)

Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice

Japanese journal of clinical oncology, 2020-05, Vol.50 (5), p.594-601

2020

Volltextzugriff (PDF)

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

Journal of thoracic oncology, 2022-04, Vol.17 (4), p.558-567

2022

Volltextzugriff (PDF)

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment

Oncoimmunology, 2020-01, Vol.9 (1), p.1722023

2020

Volltextzugriff (PDF)

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors

Cancer medicine (Malden, MA), 2022-08, Vol.11 (15), p.2944-2956

2022

Volltextzugriff (PDF)

1 – 25 von 120

Suche als RSS-Feed

Aktive Filter

KollektionEZB Electronic Journals Library

KollektionJournals@Ovid Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(114)
Mit Volltextzugriff
(112)

Publikationsform

Artikel
(120)

Sprache

Englisch
(120)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection

Differential efficacy of tyrosine kinase inhibitors (TKIs) according to the types of EGFR mutations and agents in non-small cell lung cancer (NSCLC): A real-world study

Analysis of thromboembolic events in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: A single-center real-world study

Comparison of preoperative and prechemotherapy lymphocyte counts to predict outcome of non-small cell lung cancer patients treated with adjuvant chemotherapy

Does the extent of brain metastasis affect outcome of non-small cell lung cancer patients treated with chemotherapy?

Should combination chemotherapy be used in all advanced gastric cancer patients?

Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in gastric cancer patients who underwent palliative chemotherapy

Is third-line chemotherapy routine practice in recurrent or metastatic gastric cancer?

The role of third-line chemotherapy in recurrent or metastatic gastric cancer: A cohort study with propensity score matching analysis

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

High expression of Bcl-2 to predict poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving CHOP-based chemotherapy

Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?

High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue‐based next‐generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program

MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non‐small cell lung cancer

Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors

Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS‐SPAF)

Aktive Filter

Suchergebnisse filtern